Isoliquiritigenin Attenuates UUO-Induced Renal Inflammation and Fibrosis by Inhibiting Mincle/Syk/NF-Kappa B Signaling Pathway

作者：Yunfei Liao, Ronghua Tan, LI Jing-mei, Tingting Liu, Xiaoning Zhong, Yi Yan, Jun Yang, Xi Lin, Fan Jun-ming, Ling Wang · 发表于：DOAJ (DOAJ: Directory of Open Access Journals) · 年份：2020 · 被引用次数：3 · 研究领域：Pharmacological Effects of Natural Compounds

Yuan Liao,1,* Rui-zhi Tan,1,* Jian-chun Li,1 Tong-tong Liu,1 Xia Zhong,1 Ying Yan,1 Jie-ke Yang,1 Xiao Lin,1 Jun-ming Fan,2 Li Wang1 1Research Center of Combine Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, People’s Republic of China; 2Chengdu Medical College, Chengdu, Sichuan 610000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li WangResearch Center of Combine Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, 319 # Zhongshan Road, Luzhou, Sichuan 646000, People’s Republic of ChinaTel +86 0830 3161222Email wangli120@swmu.edu.cnPurpose: Chronic kidney disease (CKD) is a global nephrotic syndrome characterized by chronic inflammation, oxidative stress and fibrosis in the kidney. Isoliquiritigenin (ISL), a flavonoid from licorice, has historically been reported to inhibit innate immune responses to inflammation and fibrosis in vivo. However, the effect of ISL on CKD progression is largely unknown.Materials and Methods: In this study, we employed the inflammatory and fibrotic models of LPS/TGF-β-induced bone marrow-derived macrophages (BMDM) in vitro and unilateral ureteral obstruction (UUO) model in vivo to explore the potential effects and mechanism of ISL on renal inflammation and fibrosis.Results: Our results manifest that ISL improved UUO-induce...